Search





Search





Abbvie To Acquire Gilgamesh Pharmaceuticals' Bretisilocin

ReutersAug 25, 2025 1:00 PM

Aug 25 (Reuters) - Abbvie Inc ABBV.N:

ABBVIE TO ACQUIRE GILGAMESH PHARMACEUTICALS' BRETISILOCIN, A NOVEL, INVESTIGATIONAL THERAPY FOR MAJOR DEPRESSIVE DISORDER, EXPANDING PSYCHIATRY PIPELINE
ABBVIE INC - TO BUY BRETISILOCIN PROGRAM FOR UP TO $1.2 BILLION
ABBVIE - GILGAMESH WILL SPIN OFF A NEW ENTITY THAT WILL OPERATE UNDER NAME GILGAMESH PHARMA INC

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Intel Stock Has Surged 74% in 2026 and Earnings Land April 23 — Is INTC Still a Buy at $68?

TradingKey - Intel surged 74% YTD and hit 26-year highs near $70. Q1 2026 earnings drop April 23. RSI overbought at 78. Key support $63, resistance $72.50. Buy or fade?

Asia-Pacific Stocks Rise Across the Board Monday as Easing Middle East Tensions Boost Market Sentiment

TradingKey - April 20: Major Asia-Pacific stock markets rose across the board on Monday, buoyed by widespread gains in global equity markets over the weekend and growing investor expectations for a de-escalation of tensions in the Middle East.

Stopping Short of $80,000. U.S.-Iran Tensions Rise, Is Bitcoin a "Halftime Break" or "Official End"?

The escalation of the US-Iran conflict triggered a surge and subsequent retreat in Bitcoin prices; whether the cryptocurrency can break through $80,000 depends on a new round of negotiations this Tuesday.

AST SpaceMobile Shares Plunge in Overnight Trading, What Happened? Will It Affect SpaceX?

TradingKey - In the early hours of April 19, AST SpaceMobile’s (ASTS.US) seventh broadband communication satellite, BlueBird 7, launched from Cape Canaveral aboard Blue Origin’s New Glenn rocket. While the rocket’s first stage was successfully recovered, the second stage deployed the satellite into

Allbirds Ditches Sneakers and Pivots to AI Computing - Is BIRD Stock Still Worth Buying After a 600% Surge?

TradingKey - Allbirds surged 600% after announcing a full pivot to GPU leasing as NewBird AI. Shares pulled back 30% the next day. Key support $10, targets $13.30 and $15.90.

Featured Tools

marketing_marketsTitle

calendar_economicCalendar

Economic Calendar

search.intelligent.strategy

article_asider_weekly_report

link

TSLA Q1 Earnings Preview: Tesla Snaps 8-Week Slump—Now Buy the Dip or Wait?

AI Chip Startup Cerebras Refiles for IPO, Testing Nvidia’s Pricing Power

Intel Q1 Earnings Preview: Triple Test of CPU, 18A Yields and Foundry Orders

Allbirds Ditches Sneakers and Pivots to AI Computing - Is BIRD Stock Still Worth Buying After a 600% Surge?

Bitcoin Breaks $78,000 Amid U.S.-Iran Conflict, Can It Return to $100,000 in 2026?

Tradingkey

Tradingkey

KeyAI

